Cargando…
HDAC6 inhibition: a significant potential regulator and therapeutic option to translate into clinical practice in renal transplantation
Histone deacetylase 6 (HDAC6), an almost exclusively cytoplasmic enzyme, plays an essential role in many biological processes and exerts its deacetylation-dependent/independent effects on a variety of target molecules, which has contributed to the flourishing growth of relatively isoform-specific en...
Autores principales: | Zhang, Qian-qian, Zhang, Wei-jie, Chang, Sheng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10401441/ https://www.ncbi.nlm.nih.gov/pubmed/37545520 http://dx.doi.org/10.3389/fimmu.2023.1168848 |
Ejemplares similares
-
HDAC Inhibition as Potential Therapeutic Strategy to Restore the Deregulated Immune Response in Severe COVID-19
por: Ripamonti, Chiara, et al.
Publicado: (2022) -
The Role of HDAC6 in Autophagy and NLRP3 Inflammasome
por: Chang, Panpan, et al.
Publicado: (2021) -
Complement Inhibition in Coronavirus Disease (COVID)-19: A Neglected Therapeutic Option
por: Stahel, Philip F., et al.
Publicado: (2020) -
Novel antimyeloma therapeutic option with inhibition of the HDAC1-IRF4 axis and PIM kinase
por: Harada, Takeshi, et al.
Publicado: (2022) -
SLE: Novel Postulates for Therapeutic Options
por: Hosszu, Kinga K., et al.
Publicado: (2020)